SAN DIEGO--(BUSINESS WIRE)-- Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX), a specialty pharmaceutical company, today announced that Richard W. Pascoe, Somaxon’s president and chief executive officer, will present at the 13th Annual BIO CEO & Investor Conference at the Waldorf Astoria Hotel in New York City on Monday, February 14, at 10:30 a.m. Eastern Time.
A live webcast of the presentation will be available in the Investor Relations section of the company’s Web site under Event Scheduler at www.somaxon.com. The webcast will be accessible one hour following conclusion of the live event and archived for approximately 30 days.
About Somaxon Pharmaceuticals, Inc.
Headquartered in San Diego, CA, Somaxon Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded pharmaceutical products and of late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area. Somaxon’s product Silenor® (doxepin), now available by prescription in the United States, is indicated for the treatment of insomnia characterized by difficulty with sleep maintenance.
For more information, please visit the company’s web site at www.somaxon.com.
Somaxon Pharmaceuticals, Inc.
Tran Nguyen, CFO, 858-876-6500
Rob Whetstone, 310-279-5963
KEYWORDS: United States North America California New York
INDUSTRY KEYWORDS: Health Biotechnology Pharmaceutical Professional Services Finance